Core Viewpoint - Arbor Realty Trust, Inc. has announced a private offering of $500 million in Senior Notes with a 7.875% interest rate, maturing in 2030, to qualified institutional buyers and non-U.S. persons [1][2] Group 1: Offering Details - The offering consists of $500 million aggregate principal amount of 7.875% Senior Notes due 2030 [1] - The Notes will be senior, unsecured obligations of Arbor Realty SR, Inc. and guaranteed by Arbor Realty Trust, Inc. on a senior, unsecured basis [1] - The expected closing date for the offering is July 9, 2025, pending customary closing conditions [1] Group 2: Use of Proceeds - A portion of the net proceeds will be used to refinance, redeem, or repay Arbor's remaining outstanding 7.50% Convertible Notes due 2025 [2] - Any remaining proceeds will be allocated for general corporate purposes [2] Group 3: Company Overview - Arbor Realty Trust, Inc. is a nationwide real estate investment trust and direct lender, focusing on loan origination and servicing for multifamily, single-family rental portfolios, and other commercial real estate assets [5] - The company manages a multibillion-dollar servicing portfolio and is a leading lender for government-sponsored enterprise products [5] - Arbor is recognized as a Fannie Mae DUS® lender and Freddie Mac Optigo® Seller/Servicer, and is an approved FHA Multifamily Accelerated Processing (MAP) lender [5]

BEIJING, July 02, 2025 (GLOBE NEWSWIRE) -- Julong Holding Limited (“Julong” or the “Company”) (Nasdaq: JLHL), a growth-oriented provider of intelligent integrated solutions, today announced that, in connection with its previously completed initial public offering (the "Offering") of its Class A ordinary shares, the underwriter has exercised its over-allotment option in full to purchase an additional 187,500 Class A ordinary shares at the public offering price from the Company, bringing additional gross proc ...

Core Viewpoint - Lixte Biotechnology Holdings, Inc. has successfully closed a private placement raising approximately $5.0 million through the sale of shares and warrants, aimed at supporting its cancer drug development efforts [1][3]. Group 1: Private Placement Details - The offering included the sale of 2,382,084 shares of Common Stock (or Pre-Funded Warrants), 3,573,130 shares of Series B Convertible Preferred Stock, and 6,355,214 Common Warrants [2]. - The Pre-Funded Warrants are immediately exercisable at a price of $0.00001, while the Common Warrants have an initial exercise price of $1.00 per share and expire 60 months after the resale registration statement is effective [2]. - The gross proceeds of approximately $5.0 million consist of $4.0 million paid at closing and $1.0 million to be paid upon the effectiveness of the resale registration statement [3]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Company Overview - Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing new cancer therapies, particularly its lead compound LB-100, which has shown promise in enhancing chemotherapy and immunotherapy outcomes [6][7]. - LB-100 is part of a new treatment paradigm in cancer biology known as activation lethality, with ongoing proof-of-concept clinical trials for various cancer types [7].

Core Points - EuroDry Ltd. has announced its annual meeting of shareholders to be held on July 23, 2025, at 11:30 a.m. in Washington, DC [1] - Shareholders of record as of June 25, 2025, are entitled to vote at the meeting [2] - The Company's Proxy Statement and annual report for the fiscal year ended December 31, 2024, are available on its website [2] Company Overview - EuroDry Ltd. was established on January 8, 2018, to consolidate the drybulk fleet of Euroseas Ltd. into a separate public company [4] - The company operates in the dry cargo and drybulk shipping market and trades on NASDAQ under the ticker EDRY [4] - EuroDry manages a fleet of 12 vessels with a total cargo capacity of 843,402 dwt, which will increase to 14 vessels and 970,402 dwt after the delivery of two Ultramax vessels in 2027 [4]

Core Insights - Emergent BioSolutions is expanding its NARCANDirect online distribution network to include KLOXXADO Nasal Spray 8 mg, enhancing access to opioid overdose response tools starting July 1, 2025 [1][2] - The addition of KLOXXADO Nasal Spray, a higher dose naloxone product, aims to provide more options for emergency responders and communities in addressing opioid emergencies [2][4] - Recent CDC data indicates a 27% decrease in drug overdose deaths in 2024, with opioid-related deaths dropping by 34%, although a subsequent increase in overdose deaths was reported, highlighting the ongoing need for effective response tools [3][4] Company Developments - Emergent acquired exclusive commercial rights to KLOXXADO Nasal Spray in January 2025, aiming to increase the availability of naloxone in the U.S. and Canada [2] - The company is also introducing Convenience Kits through NARCANDirect, which will include essential components for overdose response, such as a CPR mask and examination gloves [4] - Emergent emphasizes the importance of collaboration with various sectors to enhance community preparedness for opioid emergencies [4] Industry Context - The opioid crisis remains a significant public health challenge, necessitating continuous innovation and support in overdose response strategies [3][4] - The introduction of KLOXXADO Nasal Spray is part of a broader effort to combat the evolving nature of the opioid epidemic and improve emergency preparedness [3][4]

Fitch Ratings affirms BBB- long-term issuer rating with a stable outlookDALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, today announced that Fitch Ratings (“Fitch”) has affirmed Capital Southwest’s investment grade long-term issuer rating of BBB- with a stable out ...

EVANSVILLE, Ind., July 02, 2025 (GLOBE NEWSWIRE) -- Old National Bancorp (“Old National”), the holding company of Old National Bank, today announced the following schedule for its second-quarter 2025 earnings release and conference call: Earnings Release:Tuesday, July 22, 2025, at approximately 7:00 A.M. ET Conference Call:Tuesday, July 22, 2025, at 10:00 A.M. ET Dial-in Numbers: U.S. (800) 715-9871; International: (646) 307-1963; Access code 9394540 Webcast: Via Old National’s Investor Relations website ...

Company Overview - PrairieSky is a royalty-focused company that generates royalty revenues from petroleum and natural gas production on its properties [3] - The company has a diverse portfolio of properties with a long history of generating free cash flow, representing the largest and most concentrated independently-owned fee simple mineral title position in Canada [3] Upcoming Financial Results - PrairieSky will release its Q2 2025 results on July 14, 2025, after markets close, which will include operating and financial information [1] - Financial statements and management's discussion and analysis will be available on PrairieSky's website and SEDAR+ [1] Conference Call Details - A conference call to discuss the Q2 2025 results will be held on July 15, 2025, at 6:30 am MT (8:30 am ET) for the investment community [2] - Participants are required to register for the conference call, with details provided upon registration [2]

Core Insights - Inventiva, a clinical-stage biopharmaceutical company, announced the publication of results from the Phase 2b NATIVE clinical trial and preclinical study on lanifibranor for treating metabolic dysfunction-associated steatohepatitis (MASH) [1][10] Group 1: Clinical Trial Results - The Phase 2b NATIVE trial demonstrated that lanifibranor can reduce liver sinusoidal endothelial cell (LSEC) capillarization, which is associated with fibrosis and inflammation in patients with MASH [2][3] - CD34 staining in liver biopsies indicated a higher density in patients with MASLD or MASH compared to those without, and treatment with lanifibranor for 24 weeks resulted in a dose-dependent reduction in CD34 staining [3][6] - Histological evaluations showed that LSEC capillarization occurs early in the disease, suggesting that lanifibranor may help prevent progression to cirrhosis [6][7] Group 2: Mechanism of Action - Lanifibranor acts as a pan-PPAR agonist, targeting all three PPAR isoforms, which may contribute to its anti-fibrotic and anti-inflammatory effects [9] - Preclinical models indicated that lanifibranor not only reverses capillarization but also normalizes intrahepatic vascular resistance and portal vein pressure, outperforming single PPAR agonists [4][7] Group 3: Company Overview - Inventiva is focused on developing oral therapies for MASH and is currently evaluating lanifibranor in the pivotal Phase 3 NATiV3 clinical trial [10] - The FDA has granted Breakthrough Therapy and Fast Track designations to lanifibranor, highlighting its potential in treating MASH [9]

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Indigo Acquisition Corp. (the “Company”) announced today that it closed its initial public offering of 10,000,000 units at $10.00 per unit. The offering resulted in gross proceeds to the Company of $100,000,000. The Company’s units are listed on the Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “INACU.” Each unit consists of one ordinary share and one right entitling its holder to receive one tenth of one ordinary share upon the Company’s compl ...